Development and validation of a nine-item short screening test for ICD-11 gaming disorder (GAMES test) and estimation of the prevalence in the general young population.


Journal

Journal of behavioral addictions
ISSN: 2063-5303
Titre abrégé: J Behav Addict
Pays: Hungary
ID NLM: 101602037

Informations de publication

Date de publication:
06 Jul 2021
Historique:
received: 06 12 2020
revised: 18 04 2021
revised: 30 05 2021
accepted: 06 06 2021
pubmed: 8 7 2021
medline: 12 10 2021
entrez: 7 7 2021
Statut: epublish

Résumé

A definition of gaming disorder (GD) was introduced in ICD-11. The purpose of this study was to develop a short screening test for GD, utilizing a reference GD group. It also sought to estimate the prevalence of GD among individuals, representative of the general young population in Japan. Two hundred eighty one men and women selected from the general population, aged between 10 and 29 years, and 44 treatment seekers at our center completed a self-reported questionnaire comprising candidate questions for the screening test. The reference group with ICD-11 GD was established, based on face-to-face interviews with behavioral addiction experts, using a diagnostic interview instrument. The questions in the screening test were selected to best differentiate those who had GD from those who did not, and the cutoff value was determined using the Youden index. A nine-item screening test (GAMES test) was developed. The sensitivity and specificity of the test were both 98% and the positive predictive value in the study sample was 91%. The GAMES test comprised two factors, showed high internal consistency and was highly reproducible. The estimated prevalence of GD among the general young population was 7.6% (95% confidence interval; 6.6-8.7%) for males and 2.5% (1.9-3.2%) for females, with a combined prevalence of 5.1% (4.5-5.8%). The GAMES test shows high validity and reliability for screening of ICD-11 GD. The estimated prevalence of 5.1% among the general young population was comparable to the pooled estimates of young people globally.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
A definition of gaming disorder (GD) was introduced in ICD-11. The purpose of this study was to develop a short screening test for GD, utilizing a reference GD group. It also sought to estimate the prevalence of GD among individuals, representative of the general young population in Japan.
METHODS METHODS
Two hundred eighty one men and women selected from the general population, aged between 10 and 29 years, and 44 treatment seekers at our center completed a self-reported questionnaire comprising candidate questions for the screening test. The reference group with ICD-11 GD was established, based on face-to-face interviews with behavioral addiction experts, using a diagnostic interview instrument. The questions in the screening test were selected to best differentiate those who had GD from those who did not, and the cutoff value was determined using the Youden index.
RESULTS RESULTS
A nine-item screening test (GAMES test) was developed. The sensitivity and specificity of the test were both 98% and the positive predictive value in the study sample was 91%. The GAMES test comprised two factors, showed high internal consistency and was highly reproducible. The estimated prevalence of GD among the general young population was 7.6% (95% confidence interval; 6.6-8.7%) for males and 2.5% (1.9-3.2%) for females, with a combined prevalence of 5.1% (4.5-5.8%).
DISCUSSION AND CONCLUSION CONCLUSIONS
The GAMES test shows high validity and reliability for screening of ICD-11 GD. The estimated prevalence of 5.1% among the general young population was comparable to the pooled estimates of young people globally.

Identifiants

pubmed: 34232907
doi: 10.1556/2006.2021.00041
pmc: PMC8996803
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-280

Références

Addict Behav. 2017 Jan;64:253-260
pubmed: 26632194
Cyberpsychol Behav Soc Netw. 2016 May;19(5):335-41
pubmed: 27096439
Aust N Z J Psychiatry. 2020 Jul;54(7):707-718
pubmed: 31631668
J Clin Epidemiol. 2009 Aug;62(8):797-806
pubmed: 19447581
J Clin Med. 2019 Jun 28;8(7):
pubmed: 31261841
Psychiatry Clin Neurosci. 2017 Jul;71(7):445-458
pubmed: 27193187
Int J Environ Res Public Health. 2020 Apr 09;17(7):
pubmed: 32283803
Clin Psychol Rev. 2020 Apr;77:101831
pubmed: 32143109
J Behav Addict. 2019 Jun 1;8(2):288-294
pubmed: 31120319
Psychiatry Clin Neurosci. 2017 Jul;71(7):425-444
pubmed: 28436212
Pediatr Int. 2020 Nov;62(11):1275-1281
pubmed: 32379947
J Behav Addict. 2015 Sep;4(3):119-23
pubmed: 26014667
J Clin Med. 2020 Apr 02;9(4):
pubmed: 32252305
Acta Paediatr. 2018 Mar;107(3):511-516
pubmed: 28940637
Psychol Addict Behav. 2019 Feb;33(1):91-103
pubmed: 30589307
Psychol Assess. 2015 Jun;27(2):567-82
pubmed: 25558970
Biometrics. 2014 Mar;70(1):212-23
pubmed: 24261514
Biostatistics. 2007 Apr;8(2):474-84
pubmed: 17085745
Scand J Psychol. 2018 Oct;59(5):524-531
pubmed: 30004118
BMC Psychiatry. 2013 Jul 01;13:177
pubmed: 23816165
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
pubmed: 8923116
Biometrics. 2004 Jun;60(2):427-35
pubmed: 15180668
PLoS Med. 2013 Oct;10(10):e1001531
pubmed: 24143138
Syst Rev. 2020 Apr 2;9(1):68
pubmed: 32241295
J Behav Addict. 2017 Sep 1;6(3):271-279
pubmed: 28816494
Addict Behav. 2017 Jan;64:269-274
pubmed: 26526624
J Behav Addict. 2017 Sep 1;6(3):285-289
pubmed: 28816514

Auteurs

Susumu Higuchi (S)

1National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Kanagawa, Japan.

Yoneatsu Osaki (Y)

2Tottori University, Faculty of Medicine, Yonago, Tottori, Japan.

Aya Kinjo (A)

2Tottori University, Faculty of Medicine, Yonago, Tottori, Japan.

Satoko Mihara (S)

1National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Kanagawa, Japan.

Masaki Maezono (M)

1National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Kanagawa, Japan.

Takashi Kitayuguchi (T)

1National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Kanagawa, Japan.

Takanobu Matsuzaki (T)

1National Hospital Organization Kurihama Medical and Addiction Center, Yokosuka, Kanagawa, Japan.

Hideki Nakayama (H)

3Asahiyama Hospital, Sapporo, Hokkaido, Japan.

Hans-Jürgen Rumpf (HJ)

4University of Lübeck, Lübeck, Germany.

John B Saunders (JB)

5National Centre for Youth Substance Use Research, The University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH